Gastroesophageal reflux disease in children and adolescents: When and how to treat

Pediatric Drugs

Volumn 14, Issue 2, 2012, Pages 79-89

  Carroll, Matthew W ^a   Jacobson, Kevan ^a,b  

^a BC CHILDREN S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Adolescents; Alginate; Antacids; Children; Cimetidine; Dexlansoprazole; Esomeprazole; Famotidine; Gastro oesophageal reflux; Gastrokinetics; Histamine H2 receptor antagonists; Lansoprazole; Nizatidine; Omeprazole; Pantoprazole; Proton pump inhibitors; Rabeprazole; Ranitidine; Sucralfate

Indexed keywords

ALGINIC ACID; ANTACID AGENT; BETHANECHOL; CIMETIDINE; CISAPRIDE; DOMPERIDONE; ERYTHROMYCIN; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SUCRALFATE;

ACHLORHYDRIA; ACUTE HEPATITIS; BEHAVIOR CHANGE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIARRHEA; DRUG EFFICACY; ENTEROCOLITIS; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; HEADACHE; HEALTH CARE UTILIZATION; HUMAN; HYPERGASTRINEMIA; HYPOMAGNESEMIA; LIFESTYLE MODIFICATION; LOWER ESOPHAGUS SPHINCTER; LOWER RESPIRATORY TRACT INFECTION; MICROCYTIC ANEMIA; MILK ALKALI SYNDROME; MORBIDITY; NAUSEA; NEUROTOXICITY; OSTEOPENIA; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RICKETS; SURGICAL TECHNIQUE;

ADOLESCENT; ALGINATES; ALGORITHMS; ANTACIDS; ANTI-ULCER AGENTS; CHILD; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; ESOPHAGEAL SPHINCTER, LOWER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HISTAMINE H2 ANTAGONISTS; HUMANS; PERISTALSIS; PREVALENCE; PROTON PUMP INHIBITORS; RISK FACTORS; SUCRALFATE;

EID: 84857309340     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11594360-000000000-00000     Document Type: Review

References (95)

1. Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastroesophageal reflux during infancy: a pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 1997 Jun; 151 (6): 569-72 (Pubitemid 27262280)
2. Nelson SP, Kothari S, Wu EQ, et al. Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy. J Med Econ 2009; 12 (4): 348-55
3. Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 2000 Feb; 154 (2): 150-4 (Pubitemid 30075195)
4. Vakil N. Disease definition, clinical manifestations, epidemiology and natural history of GERD. Best Pract Res Clin Gastroenterol 2010 Dec; 24 (6): 759-64
5. Barak N, Ehrenpreis ED, Harrison JR, et al. Gastro-oesophageal reflux disease in obesity: pathophysiological and therapeutic considerations. Obes Rev 2002 Feb; 3 (1): 9-15 (Pubitemid 34827141)
6. Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in australia. Pharmacoepidemiol Drug Saf 2010 Oct; 19 (10): 1019-24
7. Sherman PM, Hassall E, Fagundes-Neto U, et al. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am J Gastroenterol 2009 May; 104 (5): 1278-95
8. Martin AJ, Pratt N, Kennedy JD, et al. Natural history and familial relationships of infant spilling to 9 years of age. Pediatrics 2002 Jun; 109 (6): 1061-7 (Pubitemid 34587431)
9. Gold BD. Review article: epidemiology and management of gastrooesophageal reflux in children. Aliment Pharmacol Ther 2004 Feb; 19 Suppl. 1: 22-7 (Pubitemid 38253488)
10. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Global Consensus Group. Am J Gastroenterol 2006 Aug; 101 (8): 1900-20
11. Orlando RC. Overview of the mechanisms of gastroesophageal reflux. Am J Med 2001 Dec 3; 111 Suppl. 8A: 174-7S
12. Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009 Oct; 49 (4): 498-547
13. Mosby I. Mosbys medical dictionary. 8th ed. St Louis (MO): Mosby/Elsevier, 2009.
14. Harnett KM, Cao W, Biancani P. Signal-transduction pathways that regulate smooth muscle function I: signal transduction in phasic (esophageal) and tonic (gastroesophageal sphincter) smooth muscles. Am J Physiol Gastrointest Liver Physiol 2005 Mar; 288 (3): G407-16 (Pubitemid 40267789)
15. Mittal RK, Holloway RH, Penagini R, et al. Transient lower esophageal sphincter relaxation. Gastroenterology 1995 Aug; 109 (2): 601-10
16. Kawahara H, Dent J, Davidson G. Mechanisms responsible for gastroesophageal reflux in children. Gastroenterology 1997; 113 (2): 399-408 (Pubitemid 27351763)
17. Biancani P, Harnett KM. Signal transduction in lower esophageal sphincter circular muscle. Part 1: oral cavity, pharynx and esophagus. GIMO, 2006 May 16 [online]. Available from URL: http://www.nature.com/gimo/con tents/pt1/full/gimo24.html [Accessed 2011 Feb 7]
18. Rieder F, Cheng L, Harnett KM, et al. Gastroesophageal reflux diseaseassociated esophagitis induces endogenous cytokine production leading to motor abnormalities. Gastroenterology 2007 Jan; 132 (1): 154-65 (Pubitemid 46108733)
19. Cheng L, Harnett KM, Cao W, et al. Hydrogen peroxide reduces lower esophageal sphincter tone in human esophagitis. Gastroenterology 2005 Nov; 129 (5): 1675-85 (Pubitemid 41597406)
20. Rieder F, Biancani P, Harnett K, et al. Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol 2010 May; 298 (5): G571-81
21. Harnett KM, Rieder F, Behar J, et al. Viewpoints on acid-induced inflammatory mediators in esophageal mucosa. J Neurogastroenterol Motil 2010 Oct; 16 (4): 374-88
22. Dodds WJ, Dent J, Hogan WJ, et al. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med 1982 Dec 16; 307 (25): 1547-52 (Pubitemid 13245429)
23. Sloan S, Kahrilas PJ. Impairment of esophageal emptying with hiatal hernia. Gastroenterology 1991 Mar; 100 (3): 596-605
24. Fein M, Ritter MP, DeMeester TR, et al. Role of the lower esophageal sphincter and hiatal hernia in the pathogenesis of gastroesophageal reflux disease. J Gastrointest Surg 1999 Jul-Aug; 3 (4): 405-10
25. Jones MP, Sloan SS, Rabine JC, et al. Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal reflux disease. Am J Gastroenterol 2001 Jun; 96 (6): 1711-7
26. Kahrilas PJ, Shi G, Manka M, et al. Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distention in reflux patients with hiatal hernia. Gastroenterology 2000 Apr; 118 (4): 688-95 (Pubitemid 30171618)
27. Paterson WG, Kolyn DM. Esophageal shortening induced by short-term intraluminal acid perfusion in opossum: a cause for hiatus hernia? Gastroenterology 1994 Dec; 107 (6): 1736-40
28. Dunne DP, Paterson WG. Acid-induced esophageal shortening in humans: a cause of hiatus hernia? Can J Gastroenterol 2000 Nov; 14 (10): 847-50 (Pubitemid 32094292)
29. Paterson WG. Role of mast cell-derived mediators in acid-induced shortening of the esophagus. Am J Physiol 1998 Feb; 274 (2 Pt 1): G385-8
30. Ruigómez A, WallanderM, Lundborg P, et al. Gastroesophageal reflux disease in children and adolescents in primary care. Scand J Gastroenterol 2010; 45 (2): 139-46
31. von Baeyer CL, Spagrud LJ. Systematic review of observational (behavioral) measures of pain for children and adolescents aged 3 to 18 years. Pain 2007 Jan; 127 (1-2): 140-50 (Pubitemid 44959437)
32. Stanford EA, Chambers CT, Craig KD. A normative analysis of the development of pain-related vocabulary in children. Pain 2005 Mar; 114 (1-2): 278-84 (Pubitemid 40279110)
33. Stanford EA, Chambers CT, Craig KD. The role of developmental factors in predicting young childrens use of a self-report scale for pain. Pain 2006 Jan; 120 (1-2): 16-23 (Pubitemid 43077165)
34. Beyer JE, McGrath PJ, Berde CB. Discordance between self-report and behavioral pain measures in children aged 3-7 years after surgery. J Pain Symptom Manage 1990 Dec; 5 (6): 350-6
35. Rasquin A, Di Lorenzo C, Forbes D, et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology 2006 Apr; 130 (5): 1527-37
36. Chang AB, Lasserson TJ, Kiljander TO, et al. Systematic review and metaanalysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux. BMJ 2006 Jan 7; 332 (7532): 11-7
37. Orenstein SR, Shalaby TM, Putnam PE. Thickened feedings as a cause of increased coughing when used as therapy for gastroesophageal reflux in infants. J Pediatr 1992 Dec; 121 (6): 913-5
38. Vanderhoof JA, Moran JR, Harris CL, et al. Efficacy of a pre-thickened infant formula: a multicenter, double-blind, randomized, placebo-controlled parallel group trial in 104 infants with symptomatic gastroesophageal reflux. Clin Pediatr (Phila) 2003 Jul-Aug; 42 (6): 483-95 (Pubitemid 36842139)
39. Chang AB, Lasserson TJ, Gaffney J, et al. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev 2005; (2): CD004823
40. Chang AB, Lasserson TJ, Gaffney J, et al. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev 2006; (4): CD004823
41. Chang AB, Lasserson TJ, Gaffney J, et al. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev 2011; (1): CD004823
42. Vemulapalli R. Diet and lifestyle modifications in the management of gastroesophageal reflux disease. Nutr Clin Pract 2008 Jun-Jul; 23 (3): 293-8
43. Festi D, Scaioli E, Baldi F, et al. Body weight, lifestyle, dietary habits and gastroesophageal reflux disease. World J Gastroenterol 2009 Apr 14; 15 (14): 1690-701
44. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006 May 8; 166 (9): 965-71
45. Tytgat GN, McColl K, Tack J, et al. New algorithm for the treatment of gastrooesophageal reflux disease. Aliment Pharmacol Ther 2008 Feb 1; 27 (3): 249-56
46. Anand G, Katz PO. Gastroesophageal reflux disease and obesity. Gastroenterol Clin North Am 2010 Mar; 39 (1): 39-46
47. Whiteman DC, Sadeghi S, Pandeya N, et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 2008 Feb; 57 (2): 173-80 (Pubitemid 351158042)
48. Smith KJ, OBrien SM, Smithers BM, et al. Interactions among smoking, obesity, and symptoms of acid reflux in barretts esophagus. Cancer Epidemiol Biomarkers Prev 2005 Nov; 14 (11 Pt 1): 2481-6 (Pubitemid 41752705)
49. Tighe MP, Afzal NA, Bevan A, et al. Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review. Paediatr Drugs 2009; 11 (3): 185-202
50. Sedman A. Aluminum toxicity in childhood. Pediatr Nephrol 1992 Jul; 6 (4): 383-93
51. American Academy of Pediatrics, Committee on Nutrition. Aluminum toxicity in infants and children. Pediatrics 1996 Mar 97:3:413-6.
52. Friedman JA, Carroll JC, Bergstrom WH. Antacid-induced hypophosphatemic rickets. Drug Nutr Interact 1985; 3 (4): 197-9 (Pubitemid 16225380)
53. Beall DP, Henslee HB, Webb HR, et al. Milk-alkali syndrome: a historical review and description of the modern version of the syndrome. Am J Med Sci 2006 May; 331 (5): 233-42 (Pubitemid 43804600)
54. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997 Jun; 112 (6): 1798-810 (Pubitemid 27240763)
55. Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol 1997 Sep; 11 Suppl. B: 66-73B
56. McCarty-Dawson D, Sue SO, Morrill B, et al. Ranitidine versus cimetidine in the healing of erosive esophagitis. Clin Ther 1996 Nov-Dec; 18 (6): 1150-60 (Pubitemid 27077118)
57. Cucchiara S, Franco MT, Terrin G, et al. Role of drug therapy in the treatment of gastro-oesophageal reflux disorder in children. Paediatr Drugs 2000 Jul-Aug; 2 (4): 263-72 (Pubitemid 30625804)
58. Khan M, Santana J, Donnellan C, et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007; (2): CD003244
59. van Pinxteren B, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastrooesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2006; (3): CD002095
60. Hyman PE, Garvey III TQ, Abrams CE. Tolerance to intravenous ranitidine. J Pediatr 1987 May; 110 (5): 794-6 (Pubitemid 17074756)
61. Sutphen JL, Dillard VL. Effect of ranitidine on twenty-four-hour gastric acidity in infants. J Pediatr 1989 Mar; 114 (3): 472-4 (Pubitemid 19083834)
62. Cucchiara S, Minella R, Iervolino C, et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child 1993 Dec; 69 (6): 655-9 (Pubitemid 24009909)
63. Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD: an overview of their pharmacology, efficacy and safety. Pharmacol Res 2009 Mar; 59 (3): 135-53
64. WolfeMM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000 Feb; 118 (2 Suppl. 1): S9-31
65. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008 Oct; 135 (4): 1383-91, 1391.e1-5
66. Israel DM, Hassall E. Omerprazole and other proton pump inhibitors: pharmacology, efficacy, and safety, with special reference to use in children. J Pediatr Gastroenterol Nutr 1998 Nov; 27 (5): 568-79 (Pubitemid 28492258)
67. Champion G, Richter JE, Vaezi MF, et al. Duodenogastroesophageal reflux: relationship to pH and importance in barretts esophagus. Gastroenterology 1994 Sep; 107 (3): 747-54 (Pubitemid 24265522)
68. Kearns GL, Winter HS. Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics. J Pediatr Gastroenterol Nutr 2003 Nov-Dec; 37 Suppl. 1: S52-9
69. Kearns GL, Leeder JS, Gaedigk A. Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab Dispos 2010 Jun; 38 (6): 894-7
70. Litalien C, Theoret Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet 2005; 44 (5): 441-66 (Pubitemid 40733732)
71. Zhao J, Li J, Hamer-Maansson JE, et al. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006 Nov; 28 (11): 1868-76 (Pubitemid 46043511)
72. Li J, Zhao J, Hamer-Maansson JE, et al. Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006 Mar; 28 (3): 419-27 (Pubitemid 44208780)
73. Pettersen G, Mouksassi MS, Theoret Y, et al. Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients. Br J Clin Pharmacol 2009 Feb; 67 (2): 216-27
74. Ward RM, Kearns GL, Tammara B, et al. A multicenter, randomized, openlabel, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease. J Clin Pharmacol 2010 Sep 17; 51 (6): 876-87
75. Tolia V, Fitzgerald J, Hassall E, et al. Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002; 35 Suppl. 4: S300-7 (Pubitemid 35416900)
76. Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. J Pediatr 2000 Dec; 137 (6): 800-7
77. Orenstein SR, Hassall E. Infants and proton pump inhibitors: tribulations, no trials. J Pediatr Gastroenterol Nutr 2007 Oct; 45 (4): 395-8 (Pubitemid 350307154)
78. Nelis GF. Ranitidine in the management of gastro-oesophageal reflux disease. Neth J Med 1985; 28 (5): 197-200 (Pubitemid 15078406)
79. Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006 Jan 1; 23 (1): 3-10 (Pubitemid 43381161)
80. Laheij RJ, Van Ijzendoorn MC, Janssen MJ, et al. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther 2003 Oct 15; 18 (8): 847-51 (Pubitemid 37323651)
81. Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007 Dec; 5 (12): 1418-23 (Pubitemid 350181606)
82. Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006 May; 117 (5): e817-20 (Pubitemid 46071346)
83. Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 2007 Mar; 150 (3): 262-7, 267.e1
84. Hibbs AM, Lorch SA. Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review. Pediatrics 2006 Aug; 118 (2): 746-52 (Pubitemid 46085434)
85. Pritchard DS, Baber N, Stephenson T. Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br J Clin Pharmacol 2005 Jun; 59 (6): 725-9 (Pubitemid 40835508)
86. Maclennan S, Augood C, Cash-Gibson L, et al. Cisapride treatment for gastrooesophageal reflux in children. Cochrane Database Syst Rev 2010; (4): CD002300
87. Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol 2005 Sep-Oct; 26 (5): 720-3 (Pubitemid 43015826)
88. Mousa H, Caniano DA, Alhajj M, et al. Effect of nissen fundoplication on gastric motor and sensory functions. J Pediatr Gastroenterol Nutr 2006 Aug; 43 (2): 185-9 (Pubitemid 44180502)
89. Di Lorenzo C, Orenstein S. Fundoplication: friend or foe? J Pediatr Gastroenterol Nutr 2002 Feb; 34 (2): 117-24 (Pubitemid 34259631)
90. Diaz DM, Gibbons TE, Heiss K, et al. Antireflux surgery outcomes in pediatric gastroesophageal reflux disease. Am J Gastroenterol 2005 Aug; 100 (8): 1844-52 (Pubitemid 41648442)
91. Suwandhi E, Ton MN, Schwarz SM. Gastroesophageal reflux in infancy and childhood. Pediatr Ann 2006 Apr; 35 (4): 259-66
92. Hassall E. Outcomes of fundoplication: causes for concern, newer options. Arch Dis Child 2005 Oct; 90 (10): 1047-52 (Pubitemid 41406613)
93. Bjornsson E, Abrahamsson H, Simren M, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebocontrolled trial. Aliment Pharmacol Ther 2006 Sep 15; 24 (6): 945-54 (Pubitemid 44326375)
94. Fossmark R, Johnsen G, Johanessen E, et al. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 2005 Jan 15; 21 (2): 149-54 (Pubitemid 40222967)
95. Marlais M, Fishman JR, Koglmeier J, et al. Reduced quality of life in children with gastro-oesophageal reflux disease. Acta Paediatr 2010 Mar; 99 (3): 418-21